The European Molecular Biology Laboratory (EMBL), Europe’s flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering minimal baculoviral genomes. These genomes were  created using modern synthetic biology techniques, and will appear in future as products “SynBac”.